IP Library Granted Patent US 7,435,589
Granted Patent B2
US 7,435,589 · App. 11/625,458 · Granted Oct 14, 2008

Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,435,589
App. No.
11/625,458
Granted
Oct 14, 2008
Kind
B2
Abstract

Described herein are genes whose expression are up-regulated or down-regulated in ovarian cancer. Related methods and compositions that can be used for diagnosis and treatment of ovarian cancer are disclosed. Also described herein are methods that can be used to identify modulators of ovarian cancer.

Claims (23)

1. A method of detecting ovarian cancer in a patient, the method comprising:

(i) detecting a nucleic acid in a first sample from the patient, wherein the nucleic acid sequence is at least 95% identical to SEQ ID NO:1, and wherein the nucleic acid encodes a G protein.coupled receptor 49; and

(ii) comparing the expression level of the nucleic acid in the-first sample to the expression level in a normal sample;

wherein an increase in the level of the nucleic acid relative to the normal sample is indicative of ovarian cancer.

2. The method of claim 1 , wherein the first sample comprises isolated nucleic acids.

3. The method of claim 2 , wherein the nucleic acids are mRNA.

4. The method of claim 2 , wherein the method further comprises the step of amplifying nucleic acids before the step of detecting the nucleic acid.

5. The method of claim 1 , wherein the nucleic acid comprises SEQ ID NO:1.

6. The method of claim 1 , wherein the detecting step is carried out by using a nucleic acid probe that hybridizes under stringent conditions to a nucleic acid comprising SEQ ID NO:1.

7. The method of claim 6 , wherein the probe is immobilized on a solid surface.

8. The method of claim 1 , wherein the patient is suspected of having ovarian cancer.

9. The method of claim 1 , wherein the patient is suspected of having ovarian cancer.

10. An isolated nucleic acid molecule, wherein the nucleic acid molecule comprises a sequence at least 99% identical to SEQ ID NO:1.

11. The nucleic acid molecule of claim 10 , wherein the nucleic acid molecule is labeled.

12. An expression vector comprising the nucleic acid of claim 10 .

13. A host cell comprising the expression vector of claim 12 .

14. A method of monitoring ovarian cancer in a human patient, the method comprising:

(i) detecting a nucleic acid in a first sample from the patient, wherein the nucleic acid sequence is at least 95% identical to SEQ ID NO:1, and wherein the nucleic acid encodes a G protein-coupled receptor 49;

(ii) comparing the expression level of the nucleic acid in the first sample to the expression level in a normal sample.

15. The method of claim 14 , wherein the sample comprises blood from the patient.

16. The method of claim 14 , wherein the nucleic acid sequence comprises SEQ ID NO:1.

17. The method of claim 14 , wherein the detecting step is carried out by using a nucleic acid probe that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:1.

18. The method of claim 17 , wherein the probe is immobilized on a solid surface.

Assignments (3)
CHANGE OF NAME Recorded Sep 18, 2014
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC
Reel/Frame 033772/0344 →
CHANGE OF NAME Recorded Dec 7, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025445/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 023649/0752 →